European regulators have begun an investigation into a possible risk of cancer in patients taking angiotensin II receptor inhibitors for …
Boehringer Ingelheim has given a robust rebuttal to a Lancet report implicating its hypertension drug Micardis (telmisartan) in scares about …
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals

